WO2003100051A1 - Traitement palliatif contre l'intolerance au gluten - Google Patents

Traitement palliatif contre l'intolerance au gluten Download PDF

Info

Publication number
WO2003100051A1
WO2003100051A1 PCT/AU2003/000633 AU0300633W WO03100051A1 WO 2003100051 A1 WO2003100051 A1 WO 2003100051A1 AU 0300633 W AU0300633 W AU 0300633W WO 03100051 A1 WO03100051 A1 WO 03100051A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptidase enzymes
peptidase
accordance
intestinal mucosa
enzymes
Prior art date
Application number
PCT/AU2003/000633
Other languages
English (en)
Inventor
Teodor Stelmasiak
Hugh James Beatty Cornell
Original Assignee
Glutagen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glutagen Pty Ltd filed Critical Glutagen Pty Ltd
Priority to EP03722068A priority Critical patent/EP1507853A4/fr
Priority to AU2003229373A priority patent/AU2003229373B2/en
Publication of WO2003100051A1 publication Critical patent/WO2003100051A1/fr
Priority to US10/996,081 priority patent/US20050191403A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the intestinal mucosa is then homogenized with an equal volume of deionized water to form an aqueous mixture, and clarified.
  • Clarification may be by any suitable means, for example filtration or centrifugation.
  • clarification is by centrifugation for about one hour at about 1500 g, using one litre buckets in a Beckman laboratory centrifuge, or equivalent.
  • the supernatant is collected and the precipitate is discarded.
  • the supernatant is then concentrated by ultra filtration, preferably using a filtration membrane of about 100 kDaltons.
  • the resulting concentrate is then freeze-dried to form a freeze-dried enzyme extract.
  • Example 1 A freeze-dried enzyme extract was obtained in accordance with the invention. The extract was then fractionated using a hydrophilic rigid allyl dextran/N,N'- methylene bisacrylamide matrix, with a fractionation range for globular proteins of 1 x 10 4 M r to 1.5 x 10 6 M r . (This corresponds to 10 to 1500 kDalton). A suitable product is sold under the trade name Sephacryl S-300 HR by Amersham Pharmacia Biotech, Inc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'une ou de plusieurs enzymes peptidases dans la fabrication d'un médicament utilisé pour traiter l'intolérance au gluten, une ou plusieurs enzymes peptidases pouvant assurer la digestion enzymatique de résidus de peptide de gluten.
PCT/AU2003/000633 2002-05-23 2003-05-23 Traitement palliatif contre l'intolerance au gluten WO2003100051A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03722068A EP1507853A4 (fr) 2002-05-23 2003-05-23 Traitement palliatif contre l'intolerance au gluten
AU2003229373A AU2003229373B2 (en) 2002-05-23 2003-05-23 Palliative treatment for gluten intolerance
US10/996,081 US20050191403A1 (en) 2002-05-23 2004-11-22 Palliative treatment for gluten intolerance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPS2523 2002-05-23
AUPS2523A AUPS252302A0 (en) 2002-05-23 2002-05-23 Palliative treatment for gluten intolerance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/996,081 Continuation US20050191403A1 (en) 2002-05-23 2004-11-22 Palliative treatment for gluten intolerance

Publications (1)

Publication Number Publication Date
WO2003100051A1 true WO2003100051A1 (fr) 2003-12-04

Family

ID=3836087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2003/000633 WO2003100051A1 (fr) 2002-05-23 2003-05-23 Traitement palliatif contre l'intolerance au gluten

Country Status (3)

Country Link
EP (1) EP1507853A4 (fr)
AU (1) AUPS252302A0 (fr)
WO (1) WO2003100051A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081185A1 (fr) * 2009-01-15 2010-07-22 Glutagen Pty Ltd Compositions destinées au traitement de l'intolérance au gluten et leurs applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0334997A (ja) * 1989-06-30 1991-02-14 Naochika Takahashi リンパ細胞活性化因子、その製造方法及びそれを用いたウィルス抗体の生産方法
JP3580900B2 (ja) * 1995-04-20 2004-10-27 ホクレン農業協同組合連合会 α−グルコシダーゼ阻害剤を含む糖を主体とする組成物を有効成分とする食品及び飼料
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AURRICCHIO S. ET AL.: "Toxicity mechanisms of wheat and other cereals in celiac disease and related enteropathies", JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol. 4, 1985, pages 923 - 930, XP002986629 *
CORDONE G. ET AL.: "Peptidase and coeliac disease", THE LANCET, vol. 1, 5 April 1975 (1975-04-05), pages 807 - 808, XP002987679 *
CORNELL H.J. AND TOWNLEY R.R.W.: "Investigation of possible intestinal peptidase deficiency in coeliac disease", CLINICA CHIMICA ACTA, vol. 43, 1973, pages 113 - 125, XP002986609 *
GREEN J.R. ET AL.: "Primary intestinal enteropeptidase deficiency", JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol. 3, 1984, pages 630 - 633, XP002986626 *
HAUSCH F. ET AL.: "Intestinal digestive resistance of immunodominant gliadin peptides", AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 283, June 2002 (2002-06-01), pages G996 - G1003, XP008015467 *
PETERS T.J. ET AL.: "Coeliac syndrome: biochemical mechanisms and the missing peptidase hypothesis revisted", GUT, vol. 25, 1984, pages 913 - 918, XP002986625 *
See also references of EP1507853A4 *
SHAN L. ET AL.: "Structural basis for Gluten intolerance in celiac sprue", SCIENCE, vol. 297, September 2002 (2002-09-01), pages 2275 - 2279, XP002294431 *
WEISER M.M. AND DOUGLAS A.P.: "An alternative mechanism for gluten toxicity in coeliac disease", THE LANCET, vol. 1, 13 March 1976 (1976-03-13), pages 567 - 569, XP008015468 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081185A1 (fr) * 2009-01-15 2010-07-22 Glutagen Pty Ltd Compositions destinées au traitement de l'intolérance au gluten et leurs applications
US10100296B2 (en) 2009-01-15 2018-10-16 Glutagen Pty Ltd Compositions for the treatment of gluten intolerance and uses thereof
US10457929B2 (en) 2009-01-15 2019-10-29 Glutagen Pty Ltd. Compositions for the treatment of gluten intolerance and uses thereof
EP4400163A1 (fr) 2009-01-15 2024-07-17 Glutagen Pty Ltd Compositions destinées au traitement de l'intolérance au gluten et leurs applications

Also Published As

Publication number Publication date
EP1507853A1 (fr) 2005-02-23
EP1507853A4 (fr) 2006-02-22
AUPS252302A0 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
JP5068174B2 (ja) Ｄｐｐ−ｉｖを阻害するペプチド中に濃縮されたタンパク質の加水分解物及びその使用
JP7429907B2 (ja) セリアックスプルー病を治療するための組成物および方法
KR960011522B1 (ko) 리파아제 및 리파아제 추출물, 그들의 제조방법 및 이를 함유한 지방물질 흡수기능장애 치료용 약제
Hernández-Ledesma et al. Effect of simulated gastrointestinal digestion on the antihypertensive properties of synthetic β-lactoglobulin peptide sequences
WO2011007612A1 (fr) Agent anti-inflammatoire pour application orale, et peptide anti-inflammatoire pour application orale
JPH09255698A (ja) 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤
US10457929B2 (en) Compositions for the treatment of gluten intolerance and uses thereof
AU2003229373B2 (en) Palliative treatment for gluten intolerance
Cornell et al. A unified hypothesis of coeliac disease with implications for management of patients
CA2338884A1 (fr) Agents ameliorant la fonction hepatique
EP1507853A1 (fr) Traitement palliatif contre l'intolerance au gluten
US20050191403A1 (en) Palliative treatment for gluten intolerance
KR20160113736A (ko) 알파-글루코시다제 관련 병리상태의 예방 및/또는 치료용 조성물
Jin Jr Separation and purification of antidiabetic bioactive peptide from salmon and cod waste
JPH09216834A (ja) 骨形成促進及び骨吸収防止剤
Cornell The aetiology of coeliac disease and its significance for therapy
EP0618229A1 (fr) Inhibiteurs d'amylase
Hsu et al. Hydrolysates from tuna cooking juice as an anti-hypertensive agent
Cornell et al. Enzyme therapy for coeliac disease: Is it ready for prime time?
JP2753372B2 (ja) アミラーゼ阻害物質及びその製造法
JP3055733B2 (ja) アレルゲン低減化した米調製物、その製造方法及びそれを含む加工食品
JP3055729B2 (ja) アレルゲン低減化米調製物、その製造方法及びそれを含む加工食品
TWI414305B (zh) 腎衰竭預防劑
US20030008811A1 (en) Agent for improving hepatic functions in chronic hepatitis and methods of using thereof
KR20240152328A (ko) 셀리악 스프루 질환 치료용 조성물 및 방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10996081

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003229373

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003722068

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003722068

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2003229373

Country of ref document: AU